Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis
Daniel Q. Huang, Nabil Noureddin, Veeral Ajmera, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 9, pp. 829-836
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Daniel Q. Huang, Amit G. Singal, Fasiha Kanwal, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 797-809
Closed Access | Times Cited: 86
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease
Zobair M. Younossi, Saleh A. Alqahtani, Khalid Alswat, et al.
Journal of Hepatology (2023) Vol. 80, Iss. 3, pp. 419-430
Closed Access | Times Cited: 67
Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease
Heejoon Jang, Yeonjin Kim, Dong Hyeon Lee, et al.
JAMA Internal Medicine (2024) Vol. 184, Iss. 4, pp. 375-375
Closed Access | Times Cited: 38
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
Hannes Hagström, Ying Shang, Hannes Hegmar, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 10, pp. 944-956
Closed Access | Times Cited: 36
Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction–associated steatotic liver disease
Xiaolong Qi, Jie Li, Cyrielle Caussy, et al.
Hepatology (2024)
Open Access | Times Cited: 19
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment
Norbert Stefan, Hannele Yki‐Järvinen, Brent A. Neuschwander‐Tetri
The Lancet Diabetes & Endocrinology (2024)
Open Access | Times Cited: 19
Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions
M H Miran Beygi, Salma Ahi, Samaneh Zolghadri, et al.
Nutrients (2024) Vol. 16, Iss. 14, pp. 2220-2220
Open Access | Times Cited: 18
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu, et al.
Hepatology International (2025)
Closed Access | Times Cited: 5
The growing range of complications of diabetes mellitus
Peter Shane Hamblin, Anthony Russell, Stella Talic, et al.
Trends in Endocrinology and Metabolism (2025)
Closed Access | Times Cited: 2
Metabolic dysfunction-associated steatotic liver disease in adults
Daniel Q. Huang, Vincent Wai‐Sun Wong, Mary E. Rinella, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access | Times Cited: 2
The pathophysiology of MASLD: an immunometabolic perspective
Julian Schwärzler, Felix Grabherr, Christoph Grander, et al.
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 4, pp. 375-386
Closed Access | Times Cited: 29
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study
Stephen A. Harrison, Juan P. Frías, Kathryn Jean Lucas, et al.
Clinical Gastroenterology and Hepatology (2024)
Open Access | Times Cited: 15
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial
Rohit Loomba, Pierre Bédossa, Katharine Grimmer, et al.
˜The œLancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 12, pp. 1090-1100
Open Access | Times Cited: 15
MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH
Rohit Loomba, Maral Amangurbanova, Ricki Bettencourt, et al.
Gut (2024) Vol. 73, Iss. 8, pp. 1343-1349
Closed Access | Times Cited: 14
Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
Hannes Hagström, Hannes Hegmar, Christophe Moreno
United European Gastroenterology Journal (2024) Vol. 12, Iss. 2, pp. 168-176
Open Access | Times Cited: 13
The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes‐related and cancer outcomes
David R. Riley, Theresa Hydes, Gema Hernadez, et al.
Liver International (2024) Vol. 44, Iss. 10, pp. 2538-2550
Open Access | Times Cited: 13
Rising tide: The global surge of type 2 diabetes in children and adolescents demands action now
Joseph M. Pappachan, Cornelius James Fernandez, Ambika P. Ashraf
World Journal of Diabetes (2024) Vol. 15, Iss. 5, pp. 797-809
Open Access | Times Cited: 10
The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease
Francisco Barrera, Javier Uribe, Nixa Olvares, et al.
Annals of Hepatology (2024) Vol. 29, Iss. 4, pp. 101501-101501
Open Access | Times Cited: 9
The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes
Lana Bridi, Saaket Agrawal, Kaleb Tesfai, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 3, pp. 369-377
Closed Access | Times Cited: 9
Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
Nobuharu Tamaki, Takefumi Kimura, Shun‐ichi Wakabayashi, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 8, pp. 1033-1041
Closed Access | Times Cited: 9
Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD
Salvatore Petta, Angelo Armandi, Elisabetta Bugianesi
Liver International (2024)
Open Access | Times Cited: 9
NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic–Metabolic Interplay
Simona Cernea
Life (2024) Vol. 14, Iss. 2, pp. 272-272
Open Access | Times Cited: 8
The relationship between nonalcoholic fatty liver disease and frailty: A systematic review and meta-analysis
Shaghayegh Khanmohammadi, Mahdi Masrour, Parisa Fallahtafti, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2025) Vol. 19, Iss. 2, pp. 103187-103187
Closed Access | Times Cited: 1
Pharmacological treatment for metabolic dysfunction–associated steatotic liver disease and related disorders: Current and emerging therapeutic options
Xiang Zhang, Harry Cheuk-Hay Lau, Jun Yu
Pharmacological Reviews (2025) Vol. 77, Iss. 2, pp. 100018-100018
Open Access | Times Cited: 1
Hepatocellular Carcinoma Screening: From Current Standard of Care to Future Directions
Michael Mohnasky, Sandra Gad, Andrew M. Moon, et al.
Journal of the American College of Radiology (2025) Vol. 22, Iss. 3, pp. 260-268
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top